N-terminal pro-brain natriuretic protein levels in Takotsubo cardiomyopathy

Thanh Ha Nguyen, Christopher J Neil, Aaron L Sverdlov, Gnanadevan Mahadavan, Yuliy Y Chirkov, Angela M Kucia, Jeanette Stansborough, John F Beltrame, Joseph B Selvanayagam, Christopher J Zeitz, Allan D Struthers, Michael P Frenneaux, John D Horowitz

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Takotsubo cardiomyopathy (TTC) is characterized by reversible left ventricular (LV) systolic dysfunction independent of fixed coronary disease or coronary spastic pathogenesis. A number of investigators have documented marked elevation of natriuretic peptide levels at presentation in such patients. We sought to determine the pattern, extent, and determinants of the release of N-terminal pro-B type natriuretic peptide/B type natriuretic peptide (NT-proBNP/BNP) in patients with TTC. We evaluated NT-proBNP/BNP release acutely and during the first 3 months in 56 patients with TTC (96% women, mean age 69 ± 11 years). The peak plasma NT-proBNP levels were compared to the pulmonary capillary wedge pressure and measures of regional and global LV systolic dysfunction (systolic wall stress, wall motion score index, and LV ejection fraction) as potential determinants of NT-proBNP/BNP release. In patients with TTC, the plasma concentrations of NT-proBNP (median 4,382 pg/ml, interquartile range 2,440 to 9,019) and BNP (median 617 pg/ml, interquartile range 426 to 1,026) were substantially elevated and increased significantly during the first 24 hours after the onset of symptoms (p = 0.001), with slow and incomplete resolution during the 3 months thereafter. The peak NT-proBNP levels exhibited no significant correlation with either pulmonary capillary wedge pressure or systolic wall stress. However, the peak NT-proBNP level correlated significantly with the simultaneous plasma normetanephrine concentrations (r = 0.53, p = 0.001) and the extent of impairment of LV systolic function, as measured by the wall motion score index (r = 0.37, p = 0.008) and LV ejection fraction (r = -0.39, p = 0.008). In conclusion, TTC is associated with marked and persistent elevation of NT-proBNP/BNP levels, which correlated with both the extent of catecholamine increase and the severity of LV systolic dysfunction.
Original languageEnglish
Pages (from-to)1316-1321
Number of pages6
JournalJournal of the American College of Cardiology
Volume108
Issue number9
Early online date24 Aug 2011
DOIs
Publication statusPublished - 1 Nov 2011

Fingerprint

Takotsubo Cardiomyopathy
Brain Natriuretic Peptide
Brain
Proteins
Left Ventricular Dysfunction
Pulmonary Wedge Pressure
Stroke Volume
Normetanephrine
Natriuretic Peptides
Muscle Spasticity
Left Ventricular Function
Catecholamines
Coronary Disease
Research Personnel
pro-brain natriuretic peptide (1-76)
peptide B

Cite this

Nguyen, T. H., Neil, C. J., Sverdlov, A. L., Mahadavan, G., Chirkov, Y. Y., Kucia, A. M., ... Horowitz, J. D. (2011). N-terminal pro-brain natriuretic protein levels in Takotsubo cardiomyopathy. Journal of the American College of Cardiology, 108(9), 1316-1321. https://doi.org/10.1016/j.amjcard.2011.06.047

N-terminal pro-brain natriuretic protein levels in Takotsubo cardiomyopathy. / Nguyen, Thanh Ha; Neil, Christopher J; Sverdlov, Aaron L; Mahadavan, Gnanadevan; Chirkov, Yuliy Y; Kucia, Angela M; Stansborough, Jeanette; Beltrame, John F; Selvanayagam, Joseph B; Zeitz, Christopher J; Struthers, Allan D; Frenneaux, Michael P; Horowitz, John D.

In: Journal of the American College of Cardiology, Vol. 108, No. 9, 01.11.2011, p. 1316-1321.

Research output: Contribution to journalArticle

Nguyen, TH, Neil, CJ, Sverdlov, AL, Mahadavan, G, Chirkov, YY, Kucia, AM, Stansborough, J, Beltrame, JF, Selvanayagam, JB, Zeitz, CJ, Struthers, AD, Frenneaux, MP & Horowitz, JD 2011, 'N-terminal pro-brain natriuretic protein levels in Takotsubo cardiomyopathy', Journal of the American College of Cardiology, vol. 108, no. 9, pp. 1316-1321. https://doi.org/10.1016/j.amjcard.2011.06.047
Nguyen, Thanh Ha ; Neil, Christopher J ; Sverdlov, Aaron L ; Mahadavan, Gnanadevan ; Chirkov, Yuliy Y ; Kucia, Angela M ; Stansborough, Jeanette ; Beltrame, John F ; Selvanayagam, Joseph B ; Zeitz, Christopher J ; Struthers, Allan D ; Frenneaux, Michael P ; Horowitz, John D. / N-terminal pro-brain natriuretic protein levels in Takotsubo cardiomyopathy. In: Journal of the American College of Cardiology. 2011 ; Vol. 108, No. 9. pp. 1316-1321.
@article{401b6914fe8e45bd9c950711ffafac51,
title = "N-terminal pro-brain natriuretic protein levels in Takotsubo cardiomyopathy",
abstract = "Takotsubo cardiomyopathy (TTC) is characterized by reversible left ventricular (LV) systolic dysfunction independent of fixed coronary disease or coronary spastic pathogenesis. A number of investigators have documented marked elevation of natriuretic peptide levels at presentation in such patients. We sought to determine the pattern, extent, and determinants of the release of N-terminal pro-B type natriuretic peptide/B type natriuretic peptide (NT-proBNP/BNP) in patients with TTC. We evaluated NT-proBNP/BNP release acutely and during the first 3 months in 56 patients with TTC (96{\%} women, mean age 69 ± 11 years). The peak plasma NT-proBNP levels were compared to the pulmonary capillary wedge pressure and measures of regional and global LV systolic dysfunction (systolic wall stress, wall motion score index, and LV ejection fraction) as potential determinants of NT-proBNP/BNP release. In patients with TTC, the plasma concentrations of NT-proBNP (median 4,382 pg/ml, interquartile range 2,440 to 9,019) and BNP (median 617 pg/ml, interquartile range 426 to 1,026) were substantially elevated and increased significantly during the first 24 hours after the onset of symptoms (p = 0.001), with slow and incomplete resolution during the 3 months thereafter. The peak NT-proBNP levels exhibited no significant correlation with either pulmonary capillary wedge pressure or systolic wall stress. However, the peak NT-proBNP level correlated significantly with the simultaneous plasma normetanephrine concentrations (r = 0.53, p = 0.001) and the extent of impairment of LV systolic function, as measured by the wall motion score index (r = 0.37, p = 0.008) and LV ejection fraction (r = -0.39, p = 0.008). In conclusion, TTC is associated with marked and persistent elevation of NT-proBNP/BNP levels, which correlated with both the extent of catecholamine increase and the severity of LV systolic dysfunction.",
author = "Nguyen, {Thanh Ha} and Neil, {Christopher J} and Sverdlov, {Aaron L} and Gnanadevan Mahadavan and Chirkov, {Yuliy Y} and Kucia, {Angela M} and Jeanette Stansborough and Beltrame, {John F} and Selvanayagam, {Joseph B} and Zeitz, {Christopher J} and Struthers, {Allan D} and Frenneaux, {Michael P} and Horowitz, {John D}",
note = "Crown Copyright {\circledC} 2011. Published by Elsevier Inc. All rights reserved.",
year = "2011",
month = "11",
day = "1",
doi = "10.1016/j.amjcard.2011.06.047",
language = "English",
volume = "108",
pages = "1316--1321",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "9",

}

TY - JOUR

T1 - N-terminal pro-brain natriuretic protein levels in Takotsubo cardiomyopathy

AU - Nguyen, Thanh Ha

AU - Neil, Christopher J

AU - Sverdlov, Aaron L

AU - Mahadavan, Gnanadevan

AU - Chirkov, Yuliy Y

AU - Kucia, Angela M

AU - Stansborough, Jeanette

AU - Beltrame, John F

AU - Selvanayagam, Joseph B

AU - Zeitz, Christopher J

AU - Struthers, Allan D

AU - Frenneaux, Michael P

AU - Horowitz, John D

N1 - Crown Copyright © 2011. Published by Elsevier Inc. All rights reserved.

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Takotsubo cardiomyopathy (TTC) is characterized by reversible left ventricular (LV) systolic dysfunction independent of fixed coronary disease or coronary spastic pathogenesis. A number of investigators have documented marked elevation of natriuretic peptide levels at presentation in such patients. We sought to determine the pattern, extent, and determinants of the release of N-terminal pro-B type natriuretic peptide/B type natriuretic peptide (NT-proBNP/BNP) in patients with TTC. We evaluated NT-proBNP/BNP release acutely and during the first 3 months in 56 patients with TTC (96% women, mean age 69 ± 11 years). The peak plasma NT-proBNP levels were compared to the pulmonary capillary wedge pressure and measures of regional and global LV systolic dysfunction (systolic wall stress, wall motion score index, and LV ejection fraction) as potential determinants of NT-proBNP/BNP release. In patients with TTC, the plasma concentrations of NT-proBNP (median 4,382 pg/ml, interquartile range 2,440 to 9,019) and BNP (median 617 pg/ml, interquartile range 426 to 1,026) were substantially elevated and increased significantly during the first 24 hours after the onset of symptoms (p = 0.001), with slow and incomplete resolution during the 3 months thereafter. The peak NT-proBNP levels exhibited no significant correlation with either pulmonary capillary wedge pressure or systolic wall stress. However, the peak NT-proBNP level correlated significantly with the simultaneous plasma normetanephrine concentrations (r = 0.53, p = 0.001) and the extent of impairment of LV systolic function, as measured by the wall motion score index (r = 0.37, p = 0.008) and LV ejection fraction (r = -0.39, p = 0.008). In conclusion, TTC is associated with marked and persistent elevation of NT-proBNP/BNP levels, which correlated with both the extent of catecholamine increase and the severity of LV systolic dysfunction.

AB - Takotsubo cardiomyopathy (TTC) is characterized by reversible left ventricular (LV) systolic dysfunction independent of fixed coronary disease or coronary spastic pathogenesis. A number of investigators have documented marked elevation of natriuretic peptide levels at presentation in such patients. We sought to determine the pattern, extent, and determinants of the release of N-terminal pro-B type natriuretic peptide/B type natriuretic peptide (NT-proBNP/BNP) in patients with TTC. We evaluated NT-proBNP/BNP release acutely and during the first 3 months in 56 patients with TTC (96% women, mean age 69 ± 11 years). The peak plasma NT-proBNP levels were compared to the pulmonary capillary wedge pressure and measures of regional and global LV systolic dysfunction (systolic wall stress, wall motion score index, and LV ejection fraction) as potential determinants of NT-proBNP/BNP release. In patients with TTC, the plasma concentrations of NT-proBNP (median 4,382 pg/ml, interquartile range 2,440 to 9,019) and BNP (median 617 pg/ml, interquartile range 426 to 1,026) were substantially elevated and increased significantly during the first 24 hours after the onset of symptoms (p = 0.001), with slow and incomplete resolution during the 3 months thereafter. The peak NT-proBNP levels exhibited no significant correlation with either pulmonary capillary wedge pressure or systolic wall stress. However, the peak NT-proBNP level correlated significantly with the simultaneous plasma normetanephrine concentrations (r = 0.53, p = 0.001) and the extent of impairment of LV systolic function, as measured by the wall motion score index (r = 0.37, p = 0.008) and LV ejection fraction (r = -0.39, p = 0.008). In conclusion, TTC is associated with marked and persistent elevation of NT-proBNP/BNP levels, which correlated with both the extent of catecholamine increase and the severity of LV systolic dysfunction.

U2 - 10.1016/j.amjcard.2011.06.047

DO - 10.1016/j.amjcard.2011.06.047

M3 - Article

C2 - 21871590

VL - 108

SP - 1316

EP - 1321

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 9

ER -